Dr. Lai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Road Northwest
Washington, DC 20007Phone+1 202-444-3735
Summary
- Catherine Lai, MD, MPH, is an Associate Professor and the Physician Leader of the Leukemia Clinical Research Unit at the University of Pennsylvania. Dr. Lai specializes in detecting, monitoring, and treating acute leukemia and myeloid malignancies in adults. Dr. Lai’s research focuses on integrating health outcomes into clinical trials with novel therapeutics, with a focus on measuring physiologic age and interventions to improve early mortality and overall survival, minimize treatment toxicity and maximize tolerability to therapy.
Most recently, Dr. Lai served as the Director of Leukemia at MedStar Georgetown University Hospital’s Lombardi Comprehensive Cancer Center in Washington, DC. She completed her Hematology/Oncology fellowship at the National Cancer Institute of the National Institutes of Health. Dr. Lai received her master’s in Public Health in Epidemiology from George Washington University.
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
- University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2008 - 2011
- George Washington University School of Medicine and Health SciencesClass of 2008
Certifications & Licensure
- PA State Medical License 2021 - 2024
- DC State Medical License 2018 - 2022
- IL State Medical License 2011 - 2020
Clinical Trials
- Assessment of Geriatric Evaluations Impact on New AML Guidance Start of enrollment: 2023 Oct 25
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- A line in shifting sand: Can we define and target TP53 mutated MDS?Sarah Skuli, Andrew Matthews, Martin Carroll, Catherine Lai
Seminars in Hematology. 2024-12-01 - 3 citationsRisk prediction for clonal cytopenia: multicenter real-world evidence.Zhuoer Xie, Rami Komrokji, Najla Al Ali, Alexandra Regelson, Susan Geyer
Blood. 2024-11-07 - Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner
Haematologica. 2024-08-01
Press Mentions
- New Drug Helps Narrow Racial Survival Disparity in Patients with Acute Myeloid LeukemiaDecember 11th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: